Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Lymphoid 1

Conditions

Neoplasms 5Melanoma 4Carcinoma, Renal Cell 4Lymphoma, Follicular 3Lymphoma 3Sarcoma 2Lymphoma, Non-Hodgkin 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Carcinoma, Hepatocellular 2Zollinger-Ellison Syndrome 1Virus Diseases 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Philadelphia Chromosome 1Multiple Myeloma 1Meningeal Carcinomatosis 1Lymphoproliferative Disorders 1Lymphomatoid Granulomatosis 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Kidney Neoplasms 1Influenza, Human 1Hepatitis B, Chronic 1Hepatitis B 1Heartburn 1Gastrointestinal Cancer Metastatic 1Epstein-Barr Virus Infections 1

Interventions

Imatinib Mesylate 142nilotinib 94Cyclophosphamide 91fludarabine phosphate 75fludarabine 67Dasatinib 63Mycophenolic Acid 60Whole-Body Irradiation 59Tacrolimus 47Busulfan 45Cyclosporine 36Peripheral Blood Stem Cell Transplantation 35Cytarabine 35Melphalan 30bosutinib 27ponatinib 26Granulocyte Colony-Stimulating Factor 26thymoglobulin 25Thiotepa 25Methotrexate 25Filgrastim 25asciminib 24Antilymphocyte Serum 24Stem Cell Transplantation 22Sirolimus 17Interferon-alpha 16sargramostim 15Cord Blood Stem Cell Transplantation 14Clofarabine 13Bone Marrow Transplantation 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Interferons × Clear all
NCT00763763 2011-10-05

AFR07

Assistance Publique - Hôpitaux de Paris

Phase 2 Completed
55 enrolled
LymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00390897 2008-11-27

Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia

PETHEMA Foundation

Phase 4 Completed
360 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡